GALC and Gaucher disease: Previous work with glucocerebrosidase had identified noeurostegine as a potential PC for Gaucher's disease conferring increased activity equivalent to that of isofagomine.41 However, due to the novel domain architecture of GALC, DGN clashes with the C-terminal lectin domain that forms part of the binding pocket, meaning the ethylene bridge modification will not be beneficial for future PCT development.